Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Acquisitions (2025)

GeneDx Holdings (WGS) has disclosed Acquisitions for 2 consecutive years, with -$339000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Acquisitions changed N/A to -$339000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$339000.0, a 97.21% increase, with the full-year FY2025 number at $32.9 million, changed N/A from a year prior.
  • Acquisitions was -$339000.0 for Q4 2025 at GeneDx Holdings, up from -$12.1 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of -$339000.0 in Q4 2025 to a low of -$12.1 million in Q4 2023.